DrugPatentWatch Database Preview
Email this page to a colleague» See Plans and Pricing
« Back to Dashboard
The generic ingredient in KINEVAC is sincalide. There are three drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the sincalide profile page.
Generic Entry Opportunity Date for 017697
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Pharmacology for NDA: 017697
Profile for product number 001
|Approval Date:||Approved Prior to Jan 1, 1982||TE:||RLD:||Yes|
|Patent:||Start Trial||Patent Expiration:||Aug 16, 2022||Product Flag?||Y||Substance Flag?||Delist Request?|
|Applicant||Tradename||Generic Name||Dosage||NDA||Approval Date||Patent No.||Patent Expiration|
|Bracco||KINEVAC||sincalide||INJECTABLE;INJECTION||017697-001||Approved Prior to Jan 1, 1982||Start Trial||Start Trial|
|>Applicant||>Tradename||>Generic Name||>Dosage||>NDA||>Approval Date||>Patent No.||>Patent Expiration|
Complete Access Available with Subscription